VEGFA and neoplasm: Vorinostat can also initiate G1/G2 cell-cycle arrest in a cell-dependent and dose-dependent manner, as well as disrupt vascular endothelial growth factor (VEGF) signalling, implying that vorinostat might also hinder tumour neovascularization (Figure 4) [93].